- Home
- HIND vs ANTX Comparison
HIND vs ANTX Comparison
Compare HIND & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 31.2M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HIND | ANTX |
|---|---|---|
| Price | $3.46 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | N/A | ★ 58.5K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.01 |
| 52 Week High | N/A | $1.55 |
Technical Indicators
Market Signals| Indicator | HIND | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 50.17 |
| Support Level | $3.62 | $1.03 |
| Resistance Level | $3.84 | $1.15 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 5.45 | 50.00 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.